Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.43 |
| ▸ | MAOA | P21397 | 4/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2799016 | 0.89 | HSD11B1 (0.47) | HSD11B1OPRM1MAOAMAOBPKM | |
| SCHEMBL2800413 | 0.83 | L3MBTL1 (0.42) | HSD11B1 | |
| SCHEMBL28855466 | 0.83 | MEN1 (0.50) | HSD11B1OPRM1KMT2A | |
| SCHEMBL18163683 | 0.81 | HSD11B1 (0.48) | HSD11B1KMT2AJAK2JAK1CCR5 | |
| SCHEMBL23697502 | 0.79 | HSD11B1 (0.47) | HSD11B1ALDH1A1KMT2AJAK2JAK1 | |
| SCHEMBL4205921 | 0.78 | OPRM1 (0.49) | OPRM1ALDH1A1KMT2ASIGMAR1CCR5 | |
| SCHEMBL28741984 | 0.77 | OPRM1 (0.53) | OPRM1PKMKMT2ASIGMAR1 | |
| SCHEMBL20660332 | 0.77 | SMN1; SMN2 (0.53) | HSD11B1KMT2AJAK2JAK1CCR5 | |
| SCHEMBL2827198 | 0.77 | SMN1; SMN2 (0.53) | HSD11B1KMT2AJAK2JAK1CCR5 | |
| SCHEMBL18154298 | 0.76 | HSD11B1 (0.41) | HSD11B1ALDH1A1KMT2ALMNAPTBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | HSD11B1 3376/4885OPRM1 1016/4885MAOA 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.